


## Attachment A-1

DIVISIONAL APPLICATION 1

5

## CLAIMS

1. A heterocyclic compound of the formula [1], or a pharmaceutically acceptable salt thereof:



10

wherein:


$R^1$  is aryl; said aryl being optionally substituted by the same or different one to three groups selected from alkyl, haloalkyl, trihaloalkyl, alkoxy, halogen and nitro;

15

Het is an oxazole which is optionally substituted by alkyl or trihaloalkyl;

D is alkylene, alkenylene, or alkynylene ; and

E is a group of the formula [4]:



[4]

20

wherein Y is oxygen or sulfur;  $R^3$  and  $R^4$  are the same or different and each being hydrogen or alkyl; Z is carboxy, alkoxycarbonyl, hydroxymethyl, carbamoyl, N-hydroxycarbamoyl, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, cyano, 1H-5-tetrazolyl, 1-alkyl-5-tetrazolyl, or 2-alkyl-5-

tetrazolyl.

2. The heterocyclic compound of claim 1, which is selected from the group consisting of compounds (1) to (4) below:

- 5       (1)     2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-(E)-4-hexenyloxy]propionic acid,  
         (2)     2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-4-hexynyloxy]propionic acid,  
         (3)     2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)hexyloxy]-propanol, and  
10       (4)     2-Methyl-2-{6-[5-methyl-2-(p-tolyl)oxazol-4-yl]hexyloxy}-propionic acid, or a pharmaceutically acceptable salt thereof.

15     3.    A therapeutic pharmaceutical composition for hyperlipidemia, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof:

20     4.    A therapeutic pharmaceutical composition for arteriosclerosis, comprising as an active ingredient a heterocyclic compound as set forth in claims 1, or a pharmaceutically acceptable salt thereof.

25     5.    A therapeutic pharmaceutical composition for ischemic heart disease, comprising as an active ingredient a heterocyclic compound as set forth claim 1, or a pharmaceutically acceptable salt thereof.

30     6.    A therapeutic pharmaceutical composition for cerebral

infarction, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

5 7. A therapeutic pharmaceutical composition for reocclusion after PTCA, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

10 8. A therapeutic pharmaceutical composition for diabetes mellitus, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

15 9 A therapeutic pahramaceutical composition for obesity, comprising as an active ingredient a heterocyclic compound as set forth in claim 1, or a pharmaceutically acceptable salt thereof.

20 10. A therapeutic pharmaceutical composition for hyperlipidemia of claim 3, which is selected from the group consisting of compounds (1) to (4) below:

(1) 2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-(E)-4-hexenyloxy]propionic acid,

25 (2) 2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)-4-hexenyloxy]propionic acid,

(3) 2-Methyl-2-[6-(5-methyl-2-phenyloxazol-4-yl)hexyloxy]-propanol, and

30 (4) 2-Methyl-2-{6-[5-methyl-2-(p-tolyl)oxazol-4-yl]hexyloxy}-propionic acid.